Product Description
a novel fusion protein of human albumin and human IFNalpha-2b. Albinterferon alfa-2b exhibits high antiviral activity, and appears to offer safety/tolerability comparable to the current standard of care, and health-related quality-of-life benefits in patients with CHC (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19275518/)
Mechanisms of Action: IFNA Agonist
Novel Mechanism: Yes
Modality: Fusion Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hepatitis C|Hepatitis A|Hepatitis B, Chronic|Hepatitis C, Chronic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2008-002039-34 |
2008-002039-34 | P2 |
Completed |
Hepatitis C, Chronic |
2010-12-03 |
2022-03-12 |
Treatments |
|
NCT00964665 |
CABF656A2206 | P2 |
Terminated |
Hepatitis A|Hepatitis B, Chronic |
2010-11-01 |
2019-03-18 |
Treatments |
|
2006-006803-35 |
ND | P2 |
Terminated |
Hepatitis C |
2009-12-11 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|